Minimises overlap and maximises comparison of the diverse approaches
Establishing consensus on monitoring parameters
A FACTT: progress in an efficient, safe and cost-effective way
Coordinating European Cell-based Tolerance-inducing Therapies efforts
A FACTT is pushing the limits, inviting you to come along and join us !
WHY A FACTT ?
The number of patients with autoimmune diseases and recipients of organ or stem-cell transplants is increasing worldwide. Currently, these patients require lifelong administration of immunosuppressive drugs. Often, these drugs are ineffective, expensive and show severe side-effects. More effective and safer therapies aimed at modifying unwanted immune responses permanently or for prolonged periods are needed.
Accumulating knowledge on mechanisms of immune tolerance has led to development of specific Cell-based Tolerance-inducing Therapies (CTT) with the specific objectives to restrain unwanted immune reactions long-term. For patients, personalised CTT will represent a breakthrough for healthcare and quality of life.
Clinical CTT studies are underway or starting in single European institutes. The used CTT products are diverse and the efficacy of therapy is monitored by different parameters. This creates the risk of redundancy in trials and suboptimal performance indicators for comparison of trial outcomes.
The main objective of A FACTT is to initiate a network that will coordinate European CTT efforts to minimise overlap and maximise comparison of the diverse approaches through establishment of consensus monitoring parameters. The A FACTT-Action will thus focus and accelerate the CTT field and ensure that the field will progress in an efficient, safe and cost-effective way.
15 PhD positions in various countries in Europe in an new EU consortium INsTRuCT
These positions are covered within the framework of Innovative Training Network (ITN) programmes funded by the European Union Horizon 2020 Programme. The INsTRuCT ITN focusses on fundamental research and clinical translation of myeloid regulatory cell (MRC)-based immunotherapies. Please click here to open the full description and the way how to apply.
If you are interested in starting a PhD in an excellent consortium that also allows you to get insights in other labs and other areas of research, like research in companies, do not hesitate to apply. Application deadline: 31 Jan 2020
The A FACTT Project
Do you like to quickly learn more about the A FACTT project ? Please click here and find all information about the project, its objectives, its background and the benefits, as well as your starting point to the scientific work being carried out.
A FACTT News
Announcements of congresses, seminars, meetings, new scientifica papers, or just project news. You can find it following this link
A FACTT Agenda & Events
Events, seminars, project meetings. Don't miss the important information on when where and how to arrive.
A FACTT Scientific
Find here an overview of scientific open access publications related to A FACTT and its main themes
How to join A FACTT
Are you interested in the A FACTT project and would you like to join us and become part of Europe's biggest network on Cell-based Tolerance-inducing Therapies ? Please apply here !
Contact A FACTT
The A FACTT project is to focus and accelerate the CTT field. Should you like to receive more information about the project, please find here the information how to contact us.
Join A FACTT today
and help focusing the CTT field !
Recent publications
Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration.
Authors: Willekens B, Presas-Rodríguez S, Mansilla MJ, Derdelinckx J, Lee WP, Nijs G, De Laere M, Wens I, Cras P, Parizel P, Van Hecke W, Ribbens A, Billiet T, Adams G, Couttenye MM, Navarro-Barriuso J, Teniente-Serra A, Quirant-Sánchez B, Lopez-Diaz de Cerio A, Inogés S, Prosper F, Kip A, Verheij H, Gross CC, Wiendl H, Van Ham MS, Ten Brinke A, Barriocanal AM, Massuet-Vilamajó A, Hens N, Berneman Z, Martínez-Cáceres E, Cools N, Ramo-Tello C; RESTORE consortium.
IN: BMJ Open. Sep 2019.
Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA.
Authors: Derdelinckx J, Mansilla MJ, De Laere M, Lee WP, Navarro-Barriuso J, Wens I, Nkansah I, Daans J, De Reu H, Jolanta Keliris A, Van Audekerke J, Vanreusel V, Pieters Z, Van der Linden A, Verhoye M, Molenberghs G, Hens N, Goossens H, Willekens B, Cras P, Ponsaerts P, Berneman ZN, Martínez-Cáceres EM, Cools N.
IN: J Neuroinflammation. Aug 2019
MAP7 and MUCL1 Are Biomarkers of Vitamin D3-Induced Tolerogenic Dendritic Cells in Multiple Sclerosis Patients.
Authors: Navarro-Barriuso J, Mansilla MJ, Quirant-Sánchez B, Ardiaca-Martínez A, Teniente-Serra A, Presas-Rodríguez S, Ten Brinke A, Ramo-Tello C, Martínez-Cáceres EM.
IN: Front Immunology June 2019
Ways Forward for Tolerance-Inducing Cellular Therapies- an AFACTT Perspective.
Authors: Ten Brinke A, Martinez-Llordella M, Cools N, Hilkens CMU, van Ham SM, Sawitzki B, Geissler EK, Lombardi G, Trzonkowski P, Martinez-Caceres E.
IN: Front Immunology Feb 2019
AFACTT`S ACHIEVEMENTS AND CONCLUDING REMARKS.
The AFACTT project has finished officially 3rd December 2017 and was running from December 2013, made possible thanks to COST funding.
However, we continue posting for another year !
Share it
